P

Precision Cancer Centers | Ashland-Bellefonte Cancer Center

Research site

(Unclaimed)

Location

122 Street Christopher Drive, Ashland, Kentucky, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Estrogen

Platinum

Neratinib

Injectafer

Palonosetron

Docetaxel

Pegfilgrastim

Luspatercept

Debio 1143

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 14 total trials

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of en...

Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Drug: Fulvestrant or an Aromatase Inhibitor (Physician Choice)

Drug: LHRH Agonist

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) befor...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Placebo

Drug: Pemetrexed